Literature DB >> 14572738

Management of acute ischaemic stroke: new guidelines from the American Stroke Association and European Stroke Initiative.

Catharina J M Klijn1, Graeme J Hankey.   

Abstract

BACKGROUND: Ischaemic stroke is an important cause of death and dependency in industrialised countries; it has a high incidence (affecting up to 0.2% of the population each year) and is commonly lethal or disabling. One in six patients die in the first month after ischaemic stroke, and half of survivors are permanently disabled despite best efforts to rehabilitate them and to prevent complications, recurrent stroke, and other serious vascular events. Optimisation of the early, and ongoing, management of patients with acute ischaemic stroke is pivotal to the reduction of both case fatality and long-term disability. RECENT DEVELOPMENTS: Guidelines for the early management of patients with ischaemic stroke have recently been published by the Stroke Council of the American Stroke Association (ASA; Adams and co-workers, Stroke 2003; 34: 1056-83) and the European Stroke Initiative (EUSI; European Stroke Initiative Executive Committee and Writing Committee, Cerebrovasc Dis 2003; 16: 311-38). Although transatlantic differences might create different interpretations, priorities, and views, the guidelines are remarkably similar, even regarding controversial issues. We believe this is not only because both groups have had the opportunity to discuss many of the controversial issues at international meetings, but also because both groups have endorsed the concept of evidence-based medicine and have based their recommendations on similar classifications of the levels of evidence for the effectiveness of interventions. This is a triumph for evidence-based medicine and a major step towards unification of acute stroke management worldwide. WHERE NEXT?: There are three main challenges in stroke management. To increase the body of reliable evidence from large randomised controlled trials (RCTs) of the safety, effectiveness, and cost of promising treatments (eg, thrombolysis, antithrombotic therapy, neuroprotection, and interventional recanalisation, alone and in combination) in a wide range of patients around the world. To facilitate the widespread development of stroke units, delivery of organised stroke care, and emergency transport of patients with stroke to appropriate stroke centres. And finally, to improve the uptake of effective therapies into clinical practice (eg, by widely disseminating the ASA and EUSI guidelines).

Entities:  

Mesh:

Year:  2003        PMID: 14572738     DOI: 10.1016/s1474-4422(03)00558-1

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  24 in total

1.  Administering antihypertensive drugs after acute ischemic stroke: timing is everything.

Authors:  Andrea Semplicini; Lorenzo Calò
Journal:  CMAJ       Date:  2005-03-01       Impact factor: 8.262

Review 2.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

3.  Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.

Authors:  Catharina Jm Klijn; Maurizio Paciaroni; Eivind Berge; Eleni Korompoki; Janika Kõrv; Avtar Lal; Jukka Putaala; David J Werring
Journal:  Eur Stroke J       Date:  2019-04-09

4.  Trends in thrombolytic use for ischemic stroke in the United States.

Authors:  Margaret C Fang; David M Cutler; Allison B Rosen
Journal:  J Hosp Med       Date:  2010-09       Impact factor: 2.960

5.  Supporting Emergency Medical Care Teams with an Integrated Status Display Providing Real-Time Access to Medical Best Practices, Workflow Tracking, and Patient Data.

Authors:  PoLiang Wu; Min-Young Nam; Jeonghwan Choi; Alex Kirlik; Lui Sha; Richard B Berlin
Journal:  J Med Syst       Date:  2017-10-17       Impact factor: 4.460

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  A randomized trial testing the superiority of a postdischarge care management model for stroke survivors.

Authors:  Kyle Allen; Susan Hazelett; David Jarjoura; Keding Hua; Kathy Wright; Janice Weinhardt; Denise Kropp
Journal:  J Stroke Cerebrovasc Dis       Date:  2009 Nov-Dec       Impact factor: 2.136

8.  Wagging the dog--moving closer to features defined by basic scientists, the protection of prodromal transient ischaemic attacks reveals itself.

Authors:  B A McLaughlin; H Kirshner
Journal:  Eur J Neurol       Date:  2008-08       Impact factor: 6.089

Review 9.  Cannabinoid receptors in acute and chronic complications of atherosclerosis.

Authors:  F Mach; F Montecucco; S Steffens
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

10.  Intensive care unit management of patients with stroke.

Authors:  Sebastian Schulz-Stübner
Journal:  Curr Treat Options Neurol       Date:  2007-11       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.